GLPBio

Apoptosis

Read More about this category

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

 

References:

1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.

2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.

3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.

4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.

5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

Research Areas

Products Related to Apoptosis(3387)

  • GC69105 structure
    GC69105FG-3019
    CAS: 946415-13-0
    Purity: >95.00%

    FG-3019 (Pamrevlumab) is a recombinant humanized antibody that can bind to connective tissue growth factor (CTGF). FG-3019 can be used for the study of idiopathic pulmonary fibrosis (IPF).

  • GC69131 structure
    GC69131Frexalimab
    CAS: 2515463-86-0
    Purity: >98.00%

    Frexalimab (SAR441344; INX-021) is a monoclonal antibody that targets the CD40 ligand (CD40L). Frexalimab has potential for use in multiple sclerosis research.

  • GC69163 structure
    GC69163GL0388
    CAS: 2886772-68-3
    Purity: >98.00%

    GL0388 es un activador de Bax que puede inducir la inserción de Bax en la membrana mitocondrial. GL0388 tiene actividad anti-proliferativa en varias células cancerosas, con valores IC50 entre 0.299-1.57 μM. GL0388 activa a Bax e induce apoptosis mediada por Bax. En vivo, GL0388 inhibe el crecimiento del tumor xenotransplantado de cáncer de mama.

  • GC69178 structure
    GC69178Glychionide A
    CAS: 119152-50-0
    Purity: >98.00%

    Glychionide A is a flavonoid glycoside found in the roots of Glycyrrhiza glabra. Glychionide A promotes apoptosis and autophagy in PANC-1 pancreatic cancer cells. Glychionide A can be used for cancer research.

  • GC69304 structure
    GC69304IW927
    CAS: 389142-48-7
    Purity: >99.00%

    IW927 es un antagonista de pequeña molécula efectivo que puede bloquear la unión entre TNF-α y TNFRc1, con un valor IC50 de 50 nM, y también puede inhibir la fosforilación de IκB inducida por TNFα, con un valor IC50 de 600 nM.

  • GC69316 structure
    GC69316JNJ-1013
    CAS: 2597343-08-1
    Purity: >99.00%

    JNJ-1013 es un inhibidor selectivo efectivo de la degradación de IRAK1, con valores IC50 respectivos para IRAK1, IRAK4 y VHL FP de 72, 443 y 1071 nM. JNJ-1013 induce apoptosis celular y aumenta la expresión del PARP clivado. JNJ-1013 reduce la expresión de IRAK1, p-IKBα y pSTAT3 (Tyr705).

  • GC69364 structure
    GC69364LDCA
    CAS: 349106-80-5
    Purity: >99.00%

    LDCA es un regulador metabólico de doble acción que puede inhibir la actividad enzimática de LDH-A y estimular la apoptosis del grupo maligno. LDCA se puede utilizar en investigaciones sobre la progresión del cáncer.

  • GC69379 structure
    GC69379Lipid 8
    CAS: 2226547-25-5
    Purity: >98.00%

    Lipid 8 es un tipo de lípido amino ionizable que se puede utilizar para sintetizar nanopartículas lipídicas.

  • GC69380 structure
    GC69380Lirentelimab
    CAS: 2283348-97-8
    Purity: >98.00%

    Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding immunoglobulin-like lectin 8 (SIGLEC8). Lirentelimab induces apoptosis of IL-5 activated eosinophils and inhibits IL-5 mediated mast cell activation. Lirentelimab can be used for research on eosinophilic gastritis and duodenitis.

  • GC69405 structure
    GC69405L-Theanine-d5
    CAS: 1217451-85-8
    Purity: >99.00%

    L-Theanine-d5 es el deuterio sustituido de L-Theanine. L-Theanine (ácido L-glutámico etilamida) es una sustancia no proteica que se encuentra en las hojas de té verde, capaz de bloquear la unión del ácido glutámico y los receptores del ácido glutámico en el cerebro, con propiedades neuroprotectoras y antioxidantes. Puede producir efectos antiestrés al inhibir la excitación neuronal cortical después de la administración oral de L-Theanine (ácido L-glutámico etilamida).

  • GC69444 structure
    GC69444MDM2-p53-IN-16
    CAS: 1917350-09-4
    Purity: >99.00%

    MDM2-p53-IN-16 es un inhibidor del complejo MDM2-p53 que disocia el complejo humano MDM2-p532 con una IC50 de 4.3 nM. MDM2-p53-IN-16 puede reactivar p53, inducir la apoptosis y detener el ciclo celular en células de glioblastoma multiforme (GBM). MDM2-p53-IN-16 se utiliza para investigaciones sobre cáncer.

  • GC69590 structure
    GC69590Nrf2 activator-2
    CAS: 2770448-53-6
    Purity: >98.00%

    Nrf2 activator-2 (compuesto O15) is a derivative of sulforaphane, an effective Nrf2 activator with an EC50 of 2.9 μM in 293 T cells. Nrf2 activator-2 effectively inhibits the interaction between Keap1 and Nrf2, thus showing an activating effect on Nrf2. Nrf2 activator-2 shows a significant decrease in ubiquitinated levels of Nrf2 in cells.

  • GC69648 structure
    GC69648p53 Activator 7
    CAS: 2849340-59-4
    Purity: >98.00%

    P53 Activator 7 es un activador de p53 mutado Y220C (MDM-2/p53), con una EC50 de 104 nM. Puede unirse a la variante mutada de p53 y restaurar su capacidad para unirse al ADN (WO2022213975A1; Ejemplo B-1).

  • GC69673 structure
    GC69673PD-1/PD-L1-IN-13
    Purity: >98.00%

    PD-1/PD-L1-IN-13 (Compuesto 43) es un inhibidor efectivo del punto de control inmunológico PD-1/PD-L1, con un valor IC50 de 10.2 nM para la interacción PD-1/PD-L1. PD-1/PD-L1-IN-13 promueve la activación de células T CD8+ y retrasa el crecimiento tumoral en el modelo de ratón Hepa1-6.

  • GC69674 structure
    GC69674PD-1/PD-L1-IN-14
    CAS: 2499965-12-5
    Purity: >98.00%

    PD-1/PD-L1-IN-14 (compuesto 17) es un inhibidor de la interacción PD-1/PD-L1 con un valor IC50 de 27.8 nM. PD-1/PD-L1-IN-14 (compuesto 17) inhibe la interacción PD-1/PD-L1, promueve la dimerización, endocitosis y degradación de PD-L1.

  • GC69675 structure
    GC69675PD1-PDL1-IN 1 TFA
    Purity: >95.00%

    PD1-PDL1-IN 1 TFA (compuesto 16) es un inhibidor efectivo del receptor de muerte celular programada 1 (PD-1). PD1-PDL1-IN 1 TFA se puede utilizar como agente inmunomodulador.

  • GC69676 structure
    GC69676PD-1/PD-L1-IN-29
    CAS: 2665734-13-2
    Purity: >98.00%

    PD-1/PD-L1-IN-29(S4-1) es un inhibidor efectivo de PD-1/PD-L1 con un valor IC50 de 6.1 nM. PD-1/PD-L1-IN-29 puede unirse a PD-L1 y romper la interacción entre PD - 1/PD-L1, inducir la dimerización y endocitosis de PD-L1, mejorar su localización en el retículo endoplásmico y promover la entrada de PD-L1 en el retículo endoplásmico. PD- 一 /PD-LIN -29 tiene actividad anticancerígena.

  • GC69677 structure
    GC69677MAX-10181
    CAS: 2171558-14-6
    Purity: >98.00%

    MAX-10181 (PD-1/PD-L1-IN-30) es un inhibidor de la unión PD-1/PD-L1 con una IC50 de 0.018 μM. MAX-10181 se puede utilizar en la investigación del cáncer y otras enfermedades relacionadas.

  • GC69705 structure
    GC69705Physalin A
    CAS: 23027-91-0
    Purity: >98.00%

    Physalin A es un withanolide aislado de Physalis alkekengi var franchetii. Induce la apoptosis celular y está relacionado con la expresión elevada de caspasa-3 y caspasa-8. También induce la autofagia, lo que se ha encontrado que contrarresta la apoptosis en células HT1080. Physalin A tiene potencial para investigar enfermedades cancerosas.

  • GC69795 structure
    GC69795(Rac)-BIO8898
    CAS: 402564-79-8
    Purity: >98.00%

    (Rac)-BIO8898 es un inhibidor de la interacción coestimuladora CD40-CD154. (Rac)-BIO8898 inhibe la unión de CD154 a CD40-Ig, con una IC50 de 25 μM.

  • GC69801 structure
    GC69801Ragifilimab
    CAS: 2207590-51-8
    Purity: >95.00%

    Ragifilimab (INCAGN-1876) is a monoclonal antibody that targets glucocorticoid-induced TNFR-related protein (GITR) as an agonist. Ragifilimab can be used in the research of advanced or metastatic solid tumors.

  • GC69841 structure
    GC69841Rubropunctatin
    CAS: 514-67-0
    Purity: >98.00%

    Rubropunctatin is an orange nitrogen-containing ketone pigment isolated from the extract of red yeast rice (Monascus purpureus). Rubropunctatin has anti-inflammatory, immunosuppressive and antioxidant effects, as well as anti-tumor activity.

  • GC69884 structure
    GC69884Shepherdin (79-87) (TFA)
    Purity: >98.00%

    Shepherdin (79-87) TFA es un fragmento de aminoácidos de Shepherdin que abarca del 79 al 87. Shepherdin es un antagonista peptídico del complejo Hsp90-Survivina. Tiene actividad antitumoral.

  • GC69899 structure
    GC69899SIRT6 activator 12q
    CAS: 2601734-99-8
    Purity: >98.00%

    El activador de SIRT6 12q es un agente activador selectivo, efectivo y con actividad oral para SIRT6. Sus valores de IC50 para SIRT1, SIRT2, SIRT3, SIRT5 y SIRT6 son respectivamente 171.20, >200, >200, >200 y 0.58 μM. El activador de SIRT6 12q inhibe el crecimiento celular y la migración celular. También induce apoptosis (muerte celular programada) y detiene el ciclo celular en la fase G2. El activador de SIRT6 12q muestra actividad anticancerígena.